health biotech news today obesity drugs glp-1 Therapies Reshape Future of Healthcare health biotech news today obesity

Phase 2 trial data (Jastreboff et al., NEJM 2023) demonstrated average weight reductions of approximately 1724% over 48 weeks notably higher than currently approved GLP-1 receptor agonists such as semaglutide, though direct comparisons are limited by differences in trial populations and designs

E., & Garcia, M

While CYP enzymes are responsible for activation, enzymes such as glutathione S-transferase (GST) contribute to the detoxification of reactive metabolites, particularly acrolein (Alnasser, 2025)

The liver is tasked with processing lipophilic (fat-soluble) environmental toxins, pharmaceutical drugs, and metabolic waste products into hydrophilic (water-soluble) compounds that can be safely excreted via urine or bile

The goal is not to overdose, but to avoid deficiencies, especially during periods of fatigue, stress, or unbalanced diet